EUVIMEDOpdag EUVIMED
Crossref

Investigation of the Potency of KALA and REV Cell‐Penetrating Peptides for In Vitro/In Vivo Delivery of an HPV Multiepitope DNA Construct

Haleh Feyzyab, Alireza Milani, Elnaz Agi, Mehrdad Hashemi, Azam Bolhassani iD

Journal of Peptide Science · 2025

DOI: 10.1002/psc.70000 ↗

At a glance

Journal article in Journal of Peptide Science, 2025. Written by Haleh Feyzyab and 4 co-authors. Institution: Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. Major MEDLINE topics: Cell-Penetrating Peptides, Vaccines, DNA, Epitopes, Papillomavirus Vaccines. Cited 1 times so far (Crossref); 72 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Developing human papillomavirus (HPV) therapeutic DNA vaccines requires an effective delivery system, such as cell‐penetrating peptides (CPPs). In the current study, the multiepitope DNA constructs harboring the immunogenic and conserved epitopes of the L1, L2, and E7 proteins of HPV16/18 (pcDNA‐L1‐L2‐E7 and pEGFP‐L1‐L2‐E7) were delivered using KALA and REV CPPs with different properties in vitro and in vivo. Herein, after confirmation of the REV/DNA and KALA/DNA complexes, their stability was investigated against DNase I and serum protease. Then, their entry into HEK‐293T eukaryotic cells was analyzed by qualitative and quantitative methods. Finally, anti‐tumor effects of the peptide/DNA complexes were investigated in the C57BL/6 mouse model. Based on the obtained data, the REV/DNA and KALA/DNA complexes at the N/P ratio of 5:1 demonstrated successful penetration into HEK‐293T cells. Furthermore, in vivo studies represented that the REV/DNA (survival rate: 75%) and KALA/DNA (survival rate: 50%) complexes provided significant protection against C3 tumors in mice. Indeed, REV CPP exhibited a higher survival rate and lower tumor volume than KALA CPP, 50 days after the C3 challenge. These findings represented the potential of KALA and REV CPPs, especially REV, as promising gene delivery systems for developing HPV therapeutic DNA vaccine candidates.

Subjects

MeSH terms (MEDLINE)

Cell-Penetrating PeptidesVaccines, DNAEpitopesPapillomavirus VaccinesHumansAnimalsHEK293 CellsMiceMice, Inbred C57BLFemaleHuman papillomavirus 16

Author keywords

KALAREVantitumor effectcancercell‐penetrating peptidehuman papillomavirus

Substances

Cell-Penetrating PeptidesVaccines, DNAEpitopesPapillomavirus Vaccines

Authors and institutions

  • Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
  • Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
  • Blood Diseases Research Center (BDRC), Iranian Comprehensive Hemophilia Care Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.

ORCID profiles: Azam Bolhassani

Cite

APA

Feyzyab, H., Milani, A., Agi, E., Hashemi, M., & Bolhassani, A. (2025). Investigation of the Potency of KALA and REV Cell‐Penetrating Peptides for In Vitro/In Vivo Delivery of an HPV Multiepitope DNA Construct. Journal of Peptide Science. https://doi.org/10.1002/psc.70000

Vancouver

Feyzyab H, Milani A, Agi E, Hashemi M, Bolhassani A. Investigation of the Potency of KALA and REV Cell‐Penetrating Peptides for In Vitro/In Vivo Delivery of an HPV Multiepitope DNA Construct. Journal of Peptide Science. 2025. doi:10.1002/psc.70000

BibTeX
@article{Feyzyab2025,
  author = {Feyzyab, Haleh and Milani, Alireza and Agi, Elnaz and Hashemi, Mehrdad and Bolhassani, Azam},
  title = {Investigation of the Potency of KALA and REV Cell‐Penetrating Peptides for In Vitro/In Vivo Delivery of an HPV Multiepitope DNA Construct},
  journal = {Journal of Peptide Science},
  year = {2025},
  doi = {10.1002/psc.70000}
}
Start for free →